- Home
- MYO vs ALLK Comparison
MYO vs ALLK Comparison
Compare MYO & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- ALLK
- Stock Information
- Founded
- MYO 2004
- ALLK 2012
- Country
- MYO United States
- ALLK United States
- Employees
- MYO N/A
- ALLK N/A
- Industry
- MYO Industrial Specialties
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- ALLK Health Care
- Exchange
- MYO Nasdaq
- ALLK Nasdaq
- Market Cap
- MYO 113.3M
- ALLK 101.0M
- IPO Year
- MYO 2017
- ALLK 2018
- Fundamental
- Price
- MYO $4.78
- ALLK $0.91
- Analyst Decision
- MYO Strong Buy
- ALLK Hold
- Analyst Count
- MYO 4
- ALLK 5
- Target Price
- MYO $7.75
- ALLK $1.67
- AVG Volume (30 Days)
- MYO 199.1K
- ALLK 703.0K
- Earning Date
- MYO 11-06-2024
- ALLK 11-06-2024
- Dividend Yield
- MYO N/A
- ALLK N/A
- EPS Growth
- MYO N/A
- ALLK N/A
- EPS
- MYO N/A
- ALLK N/A
- Revenue
- MYO $25,239,125.00
- ALLK N/A
- Revenue This Year
- MYO $53.19
- ALLK N/A
- Revenue Next Year
- MYO $39.01
- ALLK N/A
- P/E Ratio
- MYO N/A
- ALLK N/A
- Revenue Growth
- MYO 36.23
- ALLK N/A
- 52 Week Low
- MYO $2.51
- ALLK $0.54
- 52 Week High
- MYO $5.64
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- MYO 60.02
- ALLK 39.60
- Support Level
- MYO $4.56
- ALLK $1.29
- Resistance Level
- MYO $5.15
- ALLK $1.56
- Average True Range (ATR)
- MYO 0.37
- ALLK 0.13
- MACD
- MYO 0.03
- ALLK -0.07
- Stochastic Oscillator
- MYO 65.87
- ALLK 2.52
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.